MAPRx Submits Comments to CMS on Medicare Drug Price Negotiation Program

Earlier today, the MAPRx Coalition submitted to the Centers for Medicare & Medicaid Services (CMS) comments regarding the implementation of the Medicare Drug Price Negotiation Program (MDPNP) for initial price applicability year 2026.

The Coalition appreciates the opportunity to comment on how Medicare intends to negotiate with
pharmaceutical manufacturers for lower prices on selected high-cost drugs. MAPRx believes it
is critically important for beneficiaries to have access to innovative therapies and wants to
ensure that MDPNP efforts do not exacerbate barriers to patient access.

To read the full comment letter to CMS, please click here.